Topics in Anti-Cancer Research

Volume: 3

Indexed in: Book Citation Index, Science Edition (BKCI-S), Chemical Abstracts, BIOSIS Previews, EBSCO, Ulrich's Periodicals Directory.

This is the third volume of the Patent eBook Series entitled Topics in Anti-Cancer Research. This eBook comprises updated reviews on topics relevant to modern cancer research published in the journal ...
[view complete introduction]

US $

*(Excluding Mailing and Handling)

TRAIL Receptor-Induced Cell Death Regulation: An Update to Our Deadly Discussion

Pp. 3-36 (34)

Olivier Micheau, Sarah Shirley and Alexandre Morizot


The use of TRAIL/APO2L, monoclonal antibodies or peptidomimetics targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs, in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature chapter is an update to our article “Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion”, published in the journal ‘Recent Patents on Anti-Cancer Drug Discovery’, Volume 6, Number 3, September, 2011, Page 311 to 323, reviewing TRAIL DISC components that have been shown to regulate tumor cell fate upon TRAIL engagement.


APO2L, cancer, caspase, c-FLIP, chemotherapy, death domain, death effector domain, DISC, DR4, DR5, FADD, glycosylation, Lexatumumab, scaffold, Mapatumumab, therapy, TRAIL, TRAIL-R1, TRAIL-R2, TRAIL-R4.


INSERM, Faculty of Medicine and Pharmacy, University of Bourgogne, U866, Dijon, F-21079, France.